Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Val Gebski

Showing results (221-230 of 248) with videos related to

Pageof 25
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 25, 2020
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapyAngelina Tjokrowidjaja, Chee K Lee, Michael Friedlander, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2021
Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junctionMatthieu Faron, Armel Maurice Cheugoua-Zanetsie, Pierre Thirion, et al.
BMC Cancer|February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
Medical Physics|November 23, 2024
The TROG 15.01 stereotactic prostate adaptive radiotherapy utilizing kilovoltage intrafraction monitoring (SPARK) clinical trial databaseChandrima Sengupta, Doan Trang Nguyen, Yifan Li, et al.
American Journal of Obstetrics and Gynecology|October 7, 2019
Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trialAndreas Obermair, Rebecca Asher, Rene Pareja, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 23, 2021
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancerPaul A Cohen, Penelope M Webb, Madeleine King, et al.
The Lancet. Oncology|July 20, 2010
Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trialMonika Janda, Val Gebski, Alison Brand, et al.
Nature Medicine|October 20, 2025
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trialJeanne Tie, Yuxuan Wang, Jonathan M Loree, et al.
Gynecologic Oncology|February 22, 2021
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committeeJean-Emmanuel Kurtz, Val Gebski, Vladyslav Sukhin, et al.
Oncogene|June 21, 2026
HSP47 is a potential dual cell target and prognostic factor in pancreatic cancerGeorge Sharbeen, Estrella Gonzales-Aloy, Janet Youkhana, et al.
Pageof 25

Showing results (221-230 of 248) with videos related to

Sort By:
Pageof 25
European Journal of Cancer (Oxford, England : 1990)|September 25, 2020
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapyAngelina Tjokrowidjaja, Chee K Lee, Michael Friedlander, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2021
Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junctionMatthieu Faron, Armel Maurice Cheugoua-Zanetsie, Pierre Thirion, et al.
BMC Cancer|February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
Medical Physics|November 23, 2024
The TROG 15.01 stereotactic prostate adaptive radiotherapy utilizing kilovoltage intrafraction monitoring (SPARK) clinical trial databaseChandrima Sengupta, Doan Trang Nguyen, Yifan Li, et al.
American Journal of Obstetrics and Gynecology|October 7, 2019
Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trialAndreas Obermair, Rebecca Asher, Rene Pareja, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 23, 2021
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancerPaul A Cohen, Penelope M Webb, Madeleine King, et al.
The Lancet. Oncology|July 20, 2010
Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trialMonika Janda, Val Gebski, Alison Brand, et al.
Nature Medicine|October 20, 2025
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trialJeanne Tie, Yuxuan Wang, Jonathan M Loree, et al.
Gynecologic Oncology|February 22, 2021
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committeeJean-Emmanuel Kurtz, Val Gebski, Vladyslav Sukhin, et al.
Oncogene|June 21, 2026
HSP47 is a potential dual cell target and prognostic factor in pancreatic cancerGeorge Sharbeen, Estrella Gonzales-Aloy, Janet Youkhana, et al.
Pageof 25